2019 Miami CFAR/Miami Winter Symposium

EVOLVING CONCEPTS IN HIV & EMERGING VIRAL INFECTIONS

Website.pdf

AWARDEES

Robert Gallo, Institute of Human Virology at the University of Maryland School of Medicine, USA
Feodor Lynen Lecture – HIV/AIDS: Lessons from the past; Prospects for the future

Bob Siliciano, Johns Hopkins University, USA
Special Achievement Award – Curing HIV infection: Going beyond N=1

Nora Volkow, National Institute on Drug Abuse (NIDA), USA
Bill Whelan Award, UBMB Foundation – HIV/AIDS and drug abuse: The promise of integrated care

Anthony Fauci, National Institute of Allergy and Infectious Diseases, NIH, USA
Lifetime Achievement Award – Sustained ART-free HIV remission: Obstacles and opportunities

Michel Nussenzweig, The Rockefeller University, USA
Distinguished Service Award – The HIV problem

Raymond Schinazi, Emory University, USA
IUBMB Lecture – Disruptive discoveries for HIV, HCV and HBV infections

SPEAKERS

Myron Cohen, University of North Carolina, USA
The prevention of HIV: A pandemic in transition

Serena Spudich, Yale University, USA
HIV pathogenesis and persistence in the CNS: The stage is set in primary infection

S. Pahwa, University of Miami Miller School of Medicine, USA
Aging in the era of ART and the impact on immunity

Timothy Ray Brown, Berlin Patient, USA
My continuing role as cheerleader for HIV cures

Sharon Lewin, University of Melbourne, Australia
New approaches to purge persistent HIV in individuals on ART

John Mellors, University of Pittsburgh, USA
How does HIV persist and what can we do about it?

Javier Martinez-Picado, Catalan Institute for Research and Advanced Studies (ICREA) at IrsiCaixa, Spain
Hematological stem cell therapy to cure HIV infection: So close, so far

Paolo Rossi, University of Rome Tor Vergata, Italy
Pediatric HIV infection and model for HIV remission studies

Shane Crotty, La Jolla Institute for Allergy & Immunology, USA
Assessing the engines of antibody affinity maturation to vaccines: Germinal centers and Tfh cells

Barton Haynes, Duke University, USA
The path forward for HIV vaccine development

Ethel Cesarman, Weill Cornell Medicine, USA
Targeting viral oncogenic signals

Francois Villinger, Emory University, USA
Dynamics of SIV replication under ART and Post ART Interruption identifies the most likely functional viral reservoirs in vivo

Peter Kwong, National Institute of Allergy and Infectious Diseases, NIH, USA
Vaccine elicitation of antibodies capable of neutralizing diverse strains of HIV-1

Susan Moir, National Institute of Allergy and Infectious Diseases, NIH, USA
A regulatory role for IgG3 in HIV infection

Ronald Desrosiers, University of Miami Miller School of Medicine, USA
Long-term virologic suppression following AAV delivery of anti-HIV monoclonal antibodies

Michael Farzan, Scripps Research Institute, USA
AAV-expressed eCD4-Ig can suppress an established SHIV-AD8 infection after cART cessation

Matthias Götte, University of Alberta, Canada
Mechanism of action of Remdesivir (GS-5734) against Ebola virus RNAdependent RNA polymerase

Daria Hazuda, Merck & Co, Inc., USA
HIV reverse transcriptase inhibitors: Over 30 years of drug discovery and still learning

Nagalingeswaran Kumarasamy, YRG CARE, India
Impact of international clinical research on HIV treatment guidelines

David Watkins, University of Miami Miller School of Medicine, USA
Neutralizing monoclonal antibodies to prevent and treat yellow fever virus infection